Indonesia vs Mongolia: Access to anti-retroviral drugs, male
Indonesia
44.0%
in 2024
Mongolia
42.0%
in 2024
Indonesia rank
126th
Mongolia rank
128th
Access to anti-retroviral drugs, male over time
- Indonesia
- Mongolia
How they compare
Indonesia currently reports 44.0% against 42.0% in Mongolia, a difference of 2.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Mongolia ahead.
Indonesia ranks 126th and Mongolia ranks 128th of 141 countries.
Across the 3 decades both report, Indonesia averaged higher in 1 and Mongolia in 2.
Head to head by decade
| Decade | Indonesia | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.1% | 0.7% | 0.4% | Indonesia |
| 2010s | 11.2% | 22.9% | 11.7% | Mongolia |
| 2020s | 31.8% | 38.8% | 7.0% | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Indonesia or Mongolia?
- Indonesia, at 44.0% against 42.0% in Mongolia as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Indonesia and Mongolia?
- 2.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Mongolia?
- 25 years are reported by both, from 2000 to 2024.
- How do Indonesia and Mongolia rank globally for access to anti-retroviral drugs, male?
- Indonesia ranks 126th and Mongolia ranks 128th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.